Company news

Axsome Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference

October 23, 2023

Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

October 10, 2023

Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6

October 9, 2023

Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week

October 1, 2023

Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day

September 20, 2023

Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023

September 6, 2023

Axsome Therapeutics to Present at Three Upcoming Investor Conferences

September 4, 2023

Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 6, 2023

Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7

July 11, 2023

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

July 6, 2023

Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock

June 29, 2023

Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock

June 27, 2023

Axsome Therapeutics Announces Proposed Public Offering of Common Stock

June 26, 2023

Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023

May 31, 2023

Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

May 29, 2023

Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

May 7, 2023

Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference

May 2, 2023

Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month

April 30, 2023

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academ...

April 20, 2023

Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 13, 2023

Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8

April 12, 2023

Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference

February 28, 2023

Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 26, 2023

Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe

February 21, 2023

Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference

February 6, 2023

Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27

January 30, 2023

Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 A...

December 6, 2022

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

November 27, 2022

Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

November 22, 2022

Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference

November 8, 2022

Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

November 6, 2022

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

October 26, 2022

Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022

October 20, 2022

Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

October 19, 2022

Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022

October 9, 2022

Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea

October 2, 2022

Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting

September 28, 2022

Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

September 20, 2022

Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit

September 13, 2022

Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

September 7, 2022

Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research

September 6, 2022

Axsome Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

September 5, 2022

Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor

August 31, 2022

Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

August 18, 2022

Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

August 8, 2022

Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

July 27, 2022

Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders

June 27, 2022

Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event

June 21, 2022

Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting

June 5, 2022

Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder

June 1, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 48 decks. Every deck is listed under its year.